Menu
Logo

This year on EHA, we shared exciting new data on Imbruvica® (ibrutinib) in RESONATE-2

Services
Media Center
It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.[1]

Categories / tags

CP-240988 - June 2021
© Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.
Privacy PolicyLegal NoticeCookie Policy
Cookie Settings
Logo